company background image
300529 logo

Jafron BiomedicalLtd SZSE:300529 Stock Report

Last Price

CN¥27.21

Market Cap

CN¥21.1b

7D

-0.9%

1Y

17.4%

Updated

28 Jun, 2024

Data

Company Financials +

Jafron Biomedical Co.,Ltd.

SZSE:300529 Stock Report

Market Cap: CN¥21.1b

300529 Stock Overview

Engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally.

300529 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth6/6
Past Performance2/6
Financial Health5/6
Dividends3/6

Jafron Biomedical Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jafron BiomedicalLtd
Historical stock prices
Current Share PriceCN¥27.21
52 Week HighCN¥30.65
52 Week LowCN¥15.88
Beta0.17
11 Month Change-2.37%
3 Month Change22.40%
1 Year Change17.39%
33 Year Change-66.69%
5 Year Change-18.20%
Change since IPO232.47%

Recent News & Updates

Recent updates

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28
Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24
A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08
Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02
Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13
Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22
Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Shareholder Returns

300529CN Medical EquipmentCN Market
7D-0.9%-2.3%-2.2%
1Y17.4%-18.4%-17.9%

Return vs Industry: 300529 exceeded the CN Medical Equipment industry which returned -17.5% over the past year.

Return vs Market: 300529 exceeded the CN Market which returned -17.4% over the past year.

Price Volatility

Is 300529's price volatile compared to industry and market?
300529 volatility
300529 Average Weekly Movement6.3%
Medical Equipment Industry Average Movement6.1%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.0%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 300529 has not had significant price volatility in the past 3 months.

Volatility Over Time: 300529's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19892,408Fan Dongwww.jafroninternational.com

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disinfectants, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles.

Jafron Biomedical Co.,Ltd. Fundamentals Summary

How do Jafron BiomedicalLtd's earnings and revenue compare to its market cap?
300529 fundamental statistics
Market capCN¥21.07b
Earnings (TTM)CN¥524.73m
Revenue (TTM)CN¥2.09b

40.2x

P/E Ratio

10.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300529 income statement (TTM)
RevenueCN¥2.09b
Cost of RevenueCN¥431.97m
Gross ProfitCN¥1.66b
Other ExpensesCN¥1.14b
EarningsCN¥524.73m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 08, 2024

Earnings per share (EPS)0.68
Gross Margin79.37%
Net Profit Margin25.06%
Debt/Equity Ratio55.5%

How did 300529 perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

61%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.